Novartis Pharmaceuticals
An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly
Conditions: AcromegalyThe present study is planned as an expanded treatment protocol to provide acromegalicpatients for whom medical therapy is appropriate access to pasireotide LAR whileregulatory approval for pasireotide is sought.
Advanced Accelerator Applications
EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
Conditions: Neuroendocrine TumorsAdvanced Accelerator Applications is currently pursuing marketing approval for177Lu-DOTA0-Tyr3-Octreotate (Lutathera). This expanded access therapeutic protocol aimsto allow patients suffering from inoperable, somatostatin receptor positive,neuroendocrine tumors, progressive under somatostatin analogue therapy to access theinvestigational product, 177Lu-DOTA0-Tyr3-Octreotate (Lutathera), prior to its commercialavailability.
Neuraptive Therapeutics Inc.
NTX-001 to Repair Peripheral Nerve Transection(s)
Conditions: Peripheral Nerve Transections, Acute or Planned in Upper Extremity and Facial NervesThe proposed use of NTX-001 for transections of upper extremity and facial peripheralnerves, acutely or planned.
Matrix Biomed, Inc.
Treatment of Metastatic Cancer in Terminally Diagnosed Patients
Conditions: Metastatic CancerThe objective is to provide terminally diagnosed patients with a last line of treatmentwhile improving overall quality of life. Tempol can be added to any chemotherapy regimento potentially reduce side effects and overcome chemoresistance.
W.L.Gore & Associates
Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of the Thoracoabdominal and Pararenal Aortic Aneurysms (TAMBE)
Conditions: Thoracoabdominal AneurysmExpanded access tothe GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis is safe andeffective in the treatment of thoracoabdominal and pararenal aneurysms.
DBV Technologies
Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children
Conditions: Peanut AllergyThis is an open label expanded access program for male and female patients 2 years orolder, to provide continued desensitization treatment with DBV712 250 mcg.
AstraZeneca
Himalaya Early Access Program
Conditions: Unresectable Hepatocellular CarcinomaTo provide early access (i.e., before marketing authorisation) to tremelimumab 300 mg IVadministered once on Day 1 of Cycle 1 plus durvalumab 1500 mg IV followed by durvalumab1500 mg IV Q4W monotherapy in patients with unresectable HCC.
Ionis Pharmaceuticals, Inc.
Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)
Conditions: Familial Chylomicronemia SyndromeThe purpose of the Expanded Access Program is to provide pre-approval access of olezarsento eligible patients with Familial Chylomicronemia Syndrome (FCS).
Tibotec Pharmaceuticals, Ireland
TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.
Conditions: HIV InfectionsThe purpose of this study is to provide early access to TMC114 (a protease inhibitor) forHIV-1 infected patients with limited or no treatment options, who have failed multipleantiretroviral (ARV) regimens, and to evaluate the longer-term safety and tolerability ofTMC114/r in combination with other antiretrovirals
AIM ImmunoTech Inc.
Ampligen in Chronic Fatigue Syndrome
Conditions: Chronic Fatigue SyndromeThis is an open label study of Ampligen in patients with chronic fatigue syndrome.